As of Mar 16
| +0.03 / +1.83%|
The 3 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 13.00, with a high estimate of 19.50 and a low estimate of 6.00. The median estimate represents a +678.44% increase from the last price of 1.67.
The current consensus among 3 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.